Donald A. Berry

TL;DR: A marked improvement in transplant-related mortality which is related to the use of autologous peripheral blood progenitor cells is demonstrated, almost entirely due to a reduction in mortality from hepatic veno-occlusive disease.

TL;DR: I am pleased to see ethicists addressing clinical trial design and less pleased with the contribution of Drs Hey and Kimmelman, who characterize adaptive randomization in two-armed trials as unethical.

TL;DR: The I-SPY2 trial is an example of a phase II neoadjuvant trial of novel agents for breast cancer in which issues of patient safety are addressed and adaptations of phase II design enable acceleration of drug development by reducing time and cost to screen novel therapies for activity without compromising safety.

TL;DR: The Bayesian approach is described as it has been applied to the comparative analysis of implantable cardioverter defibrillators and mammographic screening, in the Cancer Intervention and Surveillance Modeling Network, in comparisons of patient outcomes data from different sources, and in designing adaptive clinical trials to support the development of ‘personalized medicine.

TL;DR: Neither GST-alpha nor GST-mu immunopositivity in tumor or nonneoplastic breast was found to correlate with relapse-free or overall survival in this clinical context; however, the apparent decreased expression of GST- alpha in malignant versus normal breast epithelial cells could have important implications in breast carcinogenesis.